Liu Wennuan, Chang Bao-Li, Cramer Scott, Koty Patrick P, Li Tao, Sun Jishan, Turner Aubrey R, Von Kap-Herr Chris, Bobby Peggy, Rao Jianyu, Zheng S Lilly, Isaacs William B, Xu Jianfeng
Center for Human Genomics, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA.
Clin Cancer Res. 2007 Sep 1;13(17):5028-33. doi: 10.1158/1078-0432.CCR-07-0300.
Chromosome 6q14-21 is commonly deleted in prostate cancers, occurring in approximately 22% of all tumors and approximately 40% of metastatic tumors. However, candidate prostate tumor suppressor genes in this region have not been identified, in part due to the large and broad nature of the deleted region implicated in previous studies.
We first used high-resolution Affymetrix single nucleotide polymorphism arrays to examine DNA from malignant and matched nonmalignant cells from 55 prostate cancer patients. We identified a small consensus region on 6q14-21 and evaluated the deletion status within the region among additional 40 tumors and normal pairs using quantitative PCR and fluorescence in situ hybridization. We finally tested the association between the deletion and Gleason score using the Fisher's exact test.
Tumors with small, interstitial deletions at 6q14-21 defined an 817-kb consensus region that is affected in 20 of 21 tumors. The MAP3K7 gene is one of five genes located in this region. In total, MAP3K7 was deleted in 32% of 95 tumors. Importantly, deletion of MAP3K7 was highly associated with higher-grade disease, occurring in 61% of tumors with Gleason score >or=8 compared with only 22% of tumors with Gleason score <or=7. The difference was highly significant (P = 0.001).
Our study provides strong evidence for the first time that a small deletion at 6q15, including the MAP3K7 gene and four other genes, is associated with high-grade prostate cancers. Although the deletion may be a marker for high-grade prostate cancer, additional studies are needed to understand its molecular mechanisms.
6号染色体q14 - 21区域在前列腺癌中常发生缺失,约22%的所有肿瘤及约40%的转移性肿瘤存在该区域缺失。然而,该区域的候选前列腺肿瘤抑制基因尚未被鉴定出来,部分原因是先前研究所涉及的缺失区域范围大且宽泛。
我们首先使用高分辨率的Affymetrix单核苷酸多态性阵列来检测55例前列腺癌患者恶性及配对的非恶性细胞的DNA。我们在6q14 - 21上确定了一个小的共有区域,并使用定量PCR和荧光原位杂交评估另外40对肿瘤和正常样本中该区域内的缺失状态。我们最终使用Fisher精确检验来检测该缺失与Gleason评分之间的关联。
在6q14 - 21处存在小的间质缺失的肿瘤确定了一个817 kb的共有区域,21个肿瘤中有20个受其影响。丝裂原活化蛋白激酶激酶激酶7(MAP3K7)基因是位于该区域的五个基因之一。总共,95个肿瘤中有32%发生了MAP3K7缺失。重要的是,MAP3K7缺失与高分级疾病高度相关,Gleason评分≥8的肿瘤中有61%发生了缺失,而Gleason评分≤7的肿瘤中只有22%发生缺失。差异具有高度显著性(P = 0.001)。
我们的研究首次提供了强有力的证据,表明6q15处的一个小缺失,包括MAP3K7基因和其他四个基因,与高分级前列腺癌相关。尽管该缺失可能是高分级前列腺癌的一个标志物,但需要进一步研究来了解其分子机制。